Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.63 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 5/20 | 0.41 |
| ▸ | PPARA | Q07869 | 4/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.38 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4367182 | 1.00 | AAK1 (0.63) | AAK1CTSDPPARGPPARAEPHX2 | |
| SCHEMBL548006 | 0.87 | AAK1 (0.68) | AAK1PPARGPPARAITGA4ITGB7 | |
| SCHEMBL3219664 | 0.87 | AAK1 (0.68) | AAK1PPARGPPARAITGA4ITGB7 | |
| SCHEMBL548007 | 0.87 | AAK1 (0.68) | AAK1PPARGPPARAITGA4ITGB7 | |
| SCHEMBL21029262 | 0.87 | AAK1 (0.60) | AAK1PPARGPPARA | |
| SCHEMBL30949486 | 0.86 | AAK1 (0.65) | AAK1CTSDPPARGPPARAEPHX2 | |
| SCHEMBL18511393 | 0.86 | AAK1 (0.65) | AAK1CTSDPPARGPPARAITGA4 | |
| SCHEMBL4368334 | 0.86 | FPR2 (0.48) | AAK1CTSDPPARGPPARAEPHX2 | |
| SCHEMBL4367158 | 0.86 | FPR2 (0.48) | AAK1CTSDPPARGPPARAEPHX2 | |
| SCHEMBL18482288 | 0.86 | AAK1 (0.45) | AAK1CTSDPPARGPPARAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301286-B2 | Piperazine derivative | ASTELLAS PHARMA INC. (JP) | 2019-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301286-B2 | Piperazine derivative | GPR4, MC4R, TRPC4 | AAK1 956/4885CTSD 2544/4885PPARG 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.